Assessment of Animal Trials Conducted on Protectivity of Potential Sub-unit and Recombinant Vaccines against Pasteurella multocida B:2

Abstract

Haemorrhagic septicaemia, caused by Pasteurella multocida serotypes B:2 and E:2, is an acute, fatal and septicaemic disease of bovines occurring as catastrophic epizootics in most tropical regions of Asia and Africa. As chemotherapeutic treatment of P. multocida infections is expensive and ineffective, prevention of disease outbreaks following immunization is the most potent tool. Although, various vaccine formulations as alum precipitated, oil adjuvant, multiple emulsion and live attenuated vaccines are currently used in the field for the prevention of disease, the ideal vaccine with better protection and long-lasting immunity is indispensable. In the present era of recombinant technology, various sub-units and recombinant vaccines have been trialed for the development of safe and efficacious vaccines. In the present review, we have assessed the immunization trials conducted in bovines as well as laboratory animals for the protectivity of several sub-unit and recombinant vaccine formulations against P. multocida B:2 using different routes of immunization and challenge. The sub-unit vaccines using outer membrane proteins (OMP) as immunogen in normal or iron-deficient conditions have been found quite protective as compared to other sub-unit immunogens. Among the recombinant OMP vaccines, rOmp87 in Freund’s adjuvant, rOmpH and rVacJ in higher concentration with adjuvant and rTbpA fragment number 1 showed higher protection in challenge studies. AroA mutant vaccines showed significant level of protection in trials where immunization and challenge route was same. A DNA vaccine expressing tbpA has also been trialled in mice showing higher protection when combined with interleukins.

Keywords: Animal Trials, haemorrhagic septicaemia, Pasteurella multocida, recombinant, sub-unit vaccines

Cite this Article

S. Kharb, S. Charan. Assessment of Animal Trials Conducted on Protectivity of Potential Sub-unit and Recombinant Vaccines against Pasteurella multocida B:2. Research and Reviews: Journal of Immunology. 2016; 6(2): 1–12p.